906 related articles for article (PubMed ID: 17558313)
41. Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment.
Chan CK; Lin SG
Eur J Ophthalmol; 2007; 17(4):674-6. PubMed ID: 17671950
[TBL] [Abstract][Full Text] [Related]
42. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.
Cunningham ET; Feiner L; Chung C; Tuomi L; Ehrlich JS
Ophthalmology; 2011 Dec; 118(12):2447-52. PubMed ID: 21872935
[TBL] [Abstract][Full Text] [Related]
43. Long-term visual outcome of pigment epithelial tears in association with anti-VEGF therapy of pigment epithelial detachment in AMD.
Gutfleisch M; Heimes B; Schumacher M; Dietzel M; Lommatzsch A; Bird A; Pauleikhoff D
Eye (Lond); 2011 Sep; 25(9):1181-6. PubMed ID: 21701525
[TBL] [Abstract][Full Text] [Related]
44. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
Stifter E; Michels S; Prager F; Georgopoulos M; Polak K; Hirn C; Schmidt-Erfurth U
Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314
[TBL] [Abstract][Full Text] [Related]
45. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
Pedersen KB; Sjølie AK; Møller F
Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
[TBL] [Abstract][Full Text] [Related]
46. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
Spaide RF; Laud K; Fine HF; Klancnik JM; Meyerle CB; Yannuzzi LA; Sorenson J; Slakter J; Fisher YL; Cooney MJ
Retina; 2006 Apr; 26(4):383-90. PubMed ID: 16603955
[TBL] [Abstract][Full Text] [Related]
47. Prediction of retinal pigment epithelial tear in serous vascularized pigment epithelium detachment.
Clemens CR; Bastian N; Alten F; Milojcic C; Heiduschka P; Eter N
Acta Ophthalmol; 2014 Feb; 92(1):e50-6. PubMed ID: 23819839
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration.
Krebs I; Lie S; Stolba U; Zeiler F; Felke S; Binder S
Acta Ophthalmol; 2009 Sep; 87(6):611-7. PubMed ID: 18937801
[TBL] [Abstract][Full Text] [Related]
49. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
Algvere PV; Steén B; Seregard S; Kvanta A
Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
[TBL] [Abstract][Full Text] [Related]
50. RPE tears after pegaptanib treatment in age-related macular degeneration.
Chang LK; Flaxel CJ; Lauer AK; Sarraf D
Retina; 2007 Sep; 27(7):857-63. PubMed ID: 17891009
[TBL] [Abstract][Full Text] [Related]
51. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration.
Shaikh S; Olson JC; Richmond PP
Indian J Ophthalmol; 2007; 55(6):470-2. PubMed ID: 17951911
[TBL] [Abstract][Full Text] [Related]
52. Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin): optical coherence tomography and fluorescein angiographic findings.
Mathews JP; Jalil A; Lavin MJ; Stanga PE
Eye (Lond); 2007 Jul; 21(7):1004-5. PubMed ID: 17479124
[No Abstract] [Full Text] [Related]
53. Retinal pigment epithelial tears after intravitreal bevacizumab injection for predominantly classic choroidal neovascularization.
Arias L; Caminal JM; Rubio M; Pujol O; Arruga J
Eur J Ophthalmol; 2007; 17(6):992-5. PubMed ID: 18050131
[TBL] [Abstract][Full Text] [Related]
54. Retinal pigment epithelial tears in ranibizumab-treated eyes.
Smith BT; Kraus CL; Apte RS
Retina; 2009 Mar; 29(3):335-9. PubMed ID: 19174716
[TBL] [Abstract][Full Text] [Related]
55. Bilateral simultaneous intravitreal injections in the office setting.
Bakri SJ; Risco M; Edwards AO; Pulido JS
Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
[TBL] [Abstract][Full Text] [Related]
56. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
[TBL] [Abstract][Full Text] [Related]
57. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
[TBL] [Abstract][Full Text] [Related]
58. Retinal pigment epithelial tear following intravitreal bevacizumab for choroidal neovascular membrane due to age-related macular degeneration.
Hannan SR; Madhusudhana KC; Lotery AJ; Newsom RS
Br J Ophthalmol; 2007 Jul; 91(7):977-8. PubMed ID: 17576713
[No Abstract] [Full Text] [Related]
59. Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis.
Chiang A; Chang LK; Yu F; Sarraf D
Retina; 2008 Oct; 28(9):1265-9. PubMed ID: 18628724
[TBL] [Abstract][Full Text] [Related]
60. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results.
Carneiro AM; Falcão MS; Brandão EM; Falcão-Reis FM
Retina; 2010 Jan; 30(1):85-92. PubMed ID: 20010320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
